Form 6-K GSK PLC For: Nov 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
UBS Downgrades GlaxoSmithKline (GSK) to Sell
November 11, 2022 8:54 AM ESTUBS analyst Michael Leuchten downgraded GlaxoSmithKline (NYSE: GSK) from Neutral to Sell.
The analyst comments "At face value GSK trades on c9x '23E PE for near double-digit EPS CAGR to '26. Compared to the EU peer group that may not seem demanding, but we think it is. We see two factors posing risks to the earnings... More
